Switching or Discontinuing Disease-Modifying Therapies for Multiple Sclerosis

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) disease-modifying therapies (DMTs) are crucial for managing the condition.
• Discontinuation or switching of these therapies is a common clinical challenge.
• Understanding reasons for cessation is vital for patient care.

Purpose of the Study:

• To review the primary reasons for discontinuing or switching MS DMTs.
• To identify procedures that can mitigate patient risks during therapy changes.
• To evaluate the safety of DMT discontinuation in stable MS patients.

Main Methods:

• Literature review of recent studies on MS DMT discontinuation.
• Analysis of clinical experience and case studies.
• Assessment of data regarding disease activity after cessation.

Main Results:

• Reasons for DMT discontinuation are multifactorial, including physician-directed switches, patient-initiated cessation, and external circumstances like insurance loss.
• Current data are insufficient to determine the safety of discontinuing DMTs in stable patients without risking disease recurrence.
• Adverse events and risk of disease recurrence must be minimized during therapy modifications.

Conclusions:

• Clinicians should guide patients to prevent unnecessary DMT cessation.
• Therapy switches require careful planning to minimize adverse events and disease recurrence.
• The long-term safety of purposeful DMT discontinuation without disease recurrence remains uncertain.